cyclobutanes

Summary

Top Publications

  1. ncbi Emerging fusarium-mycotoxins fusaproliferin, beauvericin, enniatins, and moniliformin: a review
    Marika Jestoi
    Finnish Food Safety Authority Evira, Department of Animal Diseases and Food Safety Research, Chemistry and Toxicology Unit, Helsinki, Finland
    Crit Rev Food Sci Nutr 48:21-49. 2008
  2. ncbi Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis
    K Johansson
    Department of Medicine, Obesity Unit, Karolinska Institute, Stockholm, Sweden
    Obes Rev 10:564-75. 2009
  3. ncbi Acceleration of sperm transit time and reduction of sperm reserves in the epididymis of rats exposed to sibutramine
    Fernanda F Bellentani
    Department of Morphology, Institute of Biosciences, Unesp Univ Estadual Paulista, Distrito de Rubiao Jr s n, Botucatu, SP Brazil
    J Androl 32:718-24. 2011
  4. ncbi Analysis of Fusarium avenaceum metabolites produced during wet apple core rot
    Jens Laurids Sørensen
    Technical University of Denmark, Department of Systems Biology, Center for Microbial Biotechnology, Søltofts Plads 221, DK 2800 Kgs Lyngby, Denmark
    J Agric Food Chem 57:1632-9. 2009
  5. ncbi An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action
    E Nisoli
    Center for Study and Research on Obesity, Department of Preclinical Sciences, School of Medicine, University of Milan, LITA Vialba, L Sacco Hospital, Via G B Grassi, 74, Milan 20157, Italy
    Obes Rev 1:127-39. 2000
  6. ncbi Paradoxical effect of sibutramine on autonomic cardiovascular regulation
    Andreas L Birkenfeld
    Franz Volhard Clinical Research Center, Medical Faculty of the Charite, Humboldt University, Berlin, Germany
    Circulation 106:2459-65. 2002
  7. ncbi Presence and concentrations of the Fusarium-related mycotoxins beauvericin, enniatins and moniliformin in finnish grain samples
    M Jestoi
    National Veterinary and Food Research Institute, Department of Chemistry, PO Box 45, FIN 00581 Helsinki, Finland
    Food Addit Contam 21:794-802. 2004
  8. ncbi Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study
    Denise E Wilfley
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Psychiatry 165:51-8. 2008
  9. ncbi Drug treatments for obesity: orlistat, sibutramine, and rimonabant
    Raj S Padwal
    Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
    Lancet 369:71-7. 2007
  10. pmc A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults
    April B M Grudell
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 135:1142-54. 2008

Detail Information

Publications249 found, 100 shown here

  1. ncbi Emerging fusarium-mycotoxins fusaproliferin, beauvericin, enniatins, and moniliformin: a review
    Marika Jestoi
    Finnish Food Safety Authority Evira, Department of Animal Diseases and Food Safety Research, Chemistry and Toxicology Unit, Helsinki, Finland
    Crit Rev Food Sci Nutr 48:21-49. 2008
    ..Based on the available studies, attention should be paid to the studies on the distinct significance of these compounds in the human and animal food chains...
  2. ncbi Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis
    K Johansson
    Department of Medicine, Obesity Unit, Karolinska Institute, Stockholm, Sweden
    Obes Rev 10:564-75. 2009
    ..Given the large number of patients eligible for treatment, the low NNH for rimonabant is a concern...
  3. ncbi Acceleration of sperm transit time and reduction of sperm reserves in the epididymis of rats exposed to sibutramine
    Fernanda F Bellentani
    Department of Morphology, Institute of Biosciences, Unesp Univ Estadual Paulista, Distrito de Rubiao Jr s n, Botucatu, SP Brazil
    J Androl 32:718-24. 2011
    ..In humans, use of this drug might present a threat for male fertility because sperm reserves in men are naturally lower than those in rats...
  4. ncbi Analysis of Fusarium avenaceum metabolites produced during wet apple core rot
    Jens Laurids Sørensen
    Technical University of Denmark, Department of Systems Biology, Center for Microbial Biotechnology, Søltofts Plads 221, DK 2800 Kgs Lyngby, Denmark
    J Agric Food Chem 57:1632-9. 2009
    ..During wet apple core rot, F. avenaceum produced high amounts of mycotoxins, which may pose a risk for consumers of apple or processed apple products...
  5. ncbi An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action
    E Nisoli
    Center for Study and Research on Obesity, Department of Preclinical Sciences, School of Medicine, University of Milan, LITA Vialba, L Sacco Hospital, Via G B Grassi, 74, Milan 20157, Italy
    Obes Rev 1:127-39. 2000
    ..Finally, sibutramine does not have the potential for abuse that is characteristic of amphetamine and it is indistinguishable from placebo in abuse potential studies...
  6. ncbi Paradoxical effect of sibutramine on autonomic cardiovascular regulation
    Andreas L Birkenfeld
    Franz Volhard Clinical Research Center, Medical Faculty of the Charite, Humboldt University, Berlin, Germany
    Circulation 106:2459-65. 2002
    ..Norepinephrine reuptake inhibition with sibutramine conceivably could exacerbate arterial hypertension and promote cardiovascular disease...
  7. ncbi Presence and concentrations of the Fusarium-related mycotoxins beauvericin, enniatins and moniliformin in finnish grain samples
    M Jestoi
    National Veterinary and Food Research Institute, Department of Chemistry, PO Box 45, FIN 00581 Helsinki, Finland
    Food Addit Contam 21:794-802. 2004
    ..5%) measured as infected kernels. A significant correlation was found between F. avenaceum contamination level and the concentration levels of enniatins B and B1, as well as moniliformin...
  8. ncbi Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study
    Denise E Wilfley
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Psychiatry 165:51-8. 2008
    ..This study is the first large-scale, multisite, placebo-controlled trial to test the efficacy of sibutramine in binge eating disorder...
  9. ncbi Drug treatments for obesity: orlistat, sibutramine, and rimonabant
    Raj S Padwal
    Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
    Lancet 369:71-7. 2007
    ..Only then can patients and their physicians be confident that the putative benefits of such drugs outweigh their risks and costs...
  10. pmc A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults
    April B M Grudell
    Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 135:1142-54. 2008
    ..Weight loss in response to sibutramine is highly variable. We assessed the association of specific markers of polymorphisms of candidate alpha2A adrenoreceptor, 5-HT transporter, and GNbeta3 genes and weight loss with sibutramine...
  11. ncbi Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance
    D Hansen
    Research Department of Human Nutrition and Centre for Advanced Food Science, LMC, The Royal Veterinary and Agricultural University, Frederiksberg, Denmark
    Int J Obes Relat Metab Disord 25:496-501. 2001
    ..As only 8% of the variation in 24 months weight change could be explained by the predictors, the clinical value of this information is limited...
  12. ncbi A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders
    Susan L McElroy
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    Bipolar Disord 9:426-34. 2007
    ..The objective of this study was to compare sibutramine and topiramate as adjunctive treatments for psychotropic-associated weight gain in overweight or obese outpatients with BD...
  13. ncbi Inverse agonism at α2A adrenoceptors augments the hypophagic effect of sibutramine in rats
    Sanna K Janhunen
    Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
    Obesity (Silver Spring) 19:1979-86. 2011
    ..All in all, the present data supports the ARs and 5-HT receptors involved in the effects of SIB on different aspects of caloric intake and locomotion...
  14. ncbi Changes of cytosolic calcium and contractility of young rat vas deferens by acute treatment with amphetamine, fluoxetine or sibutramine
    Neide Hyppolito Jurkiewicz
    Department of Pharmacology, Federal University of Sao Paulo UNIFESP, Rua 3 de Maio 100, 04044 020 Sao Paulo, SP, Brazil
    Eur J Pharmacol 691:52-60. 2012
    ..Therefore, the pretreatment with amphetamine, fluoxetine or sibutramine seems to affect the calcium contractility and homeostasis in young rat vas deferens...
  15. ncbi Open channel block of A-type, kv4.3, and delayed rectifier K+ channels, Kv1.3 and Kv3.1, by sibutramine
    Sung Eun Kim
    Department of Physiology, Medical Research Center, College of Medicine, The Catholic University of Korea, 505 Banpo Dong, Socho gu, Seoul 137 701, Korea
    J Pharmacol Exp Ther 321:753-62. 2007
    ..3 and Kv3.1, resulting in a crossover phenomenon. These results indicate that sibutramine acts on Kv4.3, Kv1.3, and Kv3.1 as an open channel blocker...
  16. ncbi Multiple effects of sibutramine on ejaculation and on vas deferens and seminal vesicle contractility
    Fernanda D Nojimoto
    Department of Pharmacology, Instituto de Biociencias, UNESP, Botucatu, SP 18618000, Brazil
    Toxicol Appl Pharmacol 239:233-40. 2009
    ....
  17. ncbi Organic hypomania secondary to sibutramine-citalopram interaction
    Franco Benazzi
    J Clin Psychiatry 63:165. 2002
  18. ncbi Proteome changes in rat plasma in response to sibutramine
    Jung Won Choi
    Department of Biotechnology, Daegu University, Kyungsan, Kyungbuk, Republic of Korea
    Proteomics 11:1300-12. 2011
    ....
  19. ncbi Sibutramine-induced mania episode in a bipolar patient
    Quirino Cordeiro
    Int J Neuropsychopharmacol 5:283-4. 2002
  20. ncbi Sibutramine and the sympathetic nervous system in obese humans
    William G Haynes
    Clin Auton Res 15:189-92. 2005
  21. ncbi Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper
    S A Doggrell
    School of Biomedical Sciences, University of Queensland, Australia
    Methods Find Exp Clin Pharmacol 27:119-25. 2005
    ....
  22. ncbi Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, P le C Golgi, 2 27100 Pavia, Italy
    J Pharm Pharm Sci 13:378-90. 2010
    ..Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients...
  23. ncbi Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension
    Alptekin Gursoy
    Department of Endocrinology and Metabolic Diseases, Ankara University, School of Medicine, Ankara, Turkey
    Endocr Pract 11:308-12. 2005
    ..To assess the short-term effects of sibu-tramine on blood pressure (BP) and heart rate (HR) in normotensive and controlled hypertensive obese patients by using ambulatory blood pressure monitoring (ABPM)...
  24. ncbi Comparison of lipid lowering effect of sibutramine in patients treated or not treated with statins--3 month follow-up
    S Svacina
    Charles University in Prague, First Faculty of Medicine and General Teaching Hospital, Third Medical Department, Prague, Czech Republic
    Prague Med Rep 108:333-8. 2007
    ..We can therefore preliminarily conclude that sibutramine therapy has significant positive effect on the lipid profile even in patients who were started on statins prior to initiation of sibutramine treatment...
  25. ncbi Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients
    Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Intern Med 49:1717-25. 2010
    ..To evaluate the effects of one year of treatment with sibutramine plus L-carnitine compared to sibutramine on body weight, glycemic control, and insulin resistance state in type 2 diabetic patients...
  26. ncbi Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation
    Jimmy Lee
    Department of Psychiatry, Singapore General Hospital, Singapore
    J Psychosom Res 64:107-9. 2008
    ..Moreover, as sibutramine may be used for weight management in patients on antipsychotic medications, the implications on psychotic symptoms need to be explored further. We also discuss possible pathophysiologic underpinnings...
  27. ncbi Formation of fumonisins and other secondary metabolites by Fusarium oxysporum and F. proliferatum: a comparative study
    A Waskiewicz
    Department of Chemistry, Poznan University of Life Sciences, Poznan, Poland
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess 27:608-15. 2010
    ..proliferatum and F. oxysporum (p < 0.001)...
  28. ncbi Effect of isocaloric diets and sibutramine on food intake, body mass variation and serum TNF-alpha levels in rats
    M Trapali
    Department of Pharmacology, Medical School, University of Athens, Athens, Greece
    Pharmacology 82:15-21. 2008
    ..The aim of the study was to investigate the effects of isocaloric diets and sibutramine on food intake, body mass variation and serum TNF-alpha in free-feeding rats...
  29. ncbi A sibutramine-induced delusional disorder relapse
    P Fernandez
    J Neuropsychiatry Clin Neurosci 19:88-9. 2007
  30. ncbi Effect of sibutramine on 5-hydroxyindole acetic acid levels and selected oxidative biomarkers on brain regions of female rats in the presence of zinc
    David C Guzmán
    Laboratory of Neurochemistry, National Institute of Pediatrics, Mexico City, Mexico
    Basic Clin Pharmacol Toxicol 110:421-6. 2012
    ..Our results suggest that sibutramine and zinc are associated with weight loss, an effect that was more pronounced in the group treated with both drugs. Reduction in oxidative stress may be involved in these effects...
  31. ncbi Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins
    A Casado
    Department of Physiology, Faculty of Pharmacy, University of the Basque Country, Paseo de la Universidad 7, 01006 Vitoria, Spain
    Nutr Neurosci 6:103-11. 2003
    ..The reduction in body weight and adiposity induced by sibutramine was achieved by both a reduction in food intake and an increase in energy expenditure. NPY and orexins do not seem to be involved in the anorectic effect of sibutramine...
  32. ncbi Endiandrin A, a potent glucocorticoid receptor binder isolated from the Australian plant Endiandra anthropophagorum
    Rohan A Davis
    Eskitis Institute, Griffith University, Brisbane, QLD 4111, Australia
    J Nat Prod 70:1118-21. 2007
    ..All compounds were tested in a glucocorticoid receptor binding assay and displayed IC50 values ranging from 0.9 to 35 microM...
  33. ncbi [Sibutramine-related panic attack: a clinical case of apparent resolution with paroxetine]
    Samantha Fiorentini
    Dipartimento di Scienze Psichiatriche e Medicina Psicologica, Universita La Sapienza, Roma
    Riv Psichiatr 44:64-7. 2009
    ..After six months from the suspension of the drugs, the patient can no longer be classified as affected by panic attack according to the DSM-IV criteria...
  34. ncbi Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines
    G Valsamakis
    Department of Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK
    Metabolism 53:430-4. 2004
    ..Modest weight loss is also associated with potentially favourably changes in serum adipocytokines, particularly in a rise of serum adiponectin. Reduction of waist circumference is associated with a change in serum resistin...
  35. ncbi Comparison of efficacy of sibutramine or orlistat versus their combination in obese women
    Ramazan Sari
    Department of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, Akdeniz University, Antalya, Turkey
    Endocr Res 30:159-67. 2004
    ..Sibutramine and orlistat are currently used for weight loss. We aimed to investigate the effect of orlistat and sibutramine combination therapy in treatment of obese women...
  36. ncbi Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success
    K Elfhag
    Obesity Unit, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Diabetes Obes Metab 10:498-505. 2008
    ..To study the associations between weight loss with sibutramine and orlistat with psychological aspects that may interact with patients' response to these drugs...
  37. ncbi A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin
    Steven J McNulty
    Diabetes and Endocrinology Research Group, Department of Medicine, University Hospital Aintree, Liverpool, UK
    Diabetes Care 26:125-31. 2003
    ..To evaluate the effects of sibutramine (15 and 20 mg/day) on weight, metabolic control, and blood pressure in metformin-treated obese subjects with type 2 diabetes...
  38. ncbi Effects of sibutramine treatment in obese adolescents: a randomized trial
    Robert I Berkowitz
    The Behavioral Health Center, The Children s Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Ann Intern Med 145:81-90. 2006
    ..Increased prevalence of adolescent obesity requires effective treatment options beyond behavior therapy...
  39. ncbi Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood
    Kristina Elfhag
    Obesity Unit, Karolinska Institutet M73, Karolinska University Hospital, SE 141 86 Stockholm, Sweden
    Pharmacol Res 51:159-63. 2005
    ..Physiologically enhanced satiety could have the greatest weight loss effect for patients whose eating is more governed by hunger drives and appetite rather that by conscious efforts and cognitive control...
  40. ncbi The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea
    B J Yee
    Sleep and Circadian Research Group, Woolcock Institute of Medical Research, University of Sydney, New South Wales, Australia
    Int J Obes (Lond) 31:161-8. 2007
    ..We aimed to assess the changes in OSA and cardiovascular parameters in obese men with OSA enrolled in a sibutramine-assisted weight loss programme (SIB-WL)...
  41. ncbi Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease
    Michael Shechter
    Heart Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Am J Cardiol 97:1650-3. 2006
    ..035). Thus, short-term therapy with sibutramine, together with diet and lifestyle intervention, is associated with improved endothelial function assessed by brachial artery %FMD in nonhypertensive, stable patients with CAD...
  42. ncbi Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials
    R Padwal
    Division of Internal Medicine, University of Alberta Hospital, 2E3 Walter C Mackenzie Health Sciences Centre, Edmonton, AB, Canada
    Int J Obes Relat Metab Disord 27:1437-46. 2003
    ..Safe and effective strategies to curb rising obesity prevalence rates are urgently needed and medications may play a more prominent role in future therapeutic regimens...
  43. ncbi Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women
    D M Kim
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Yongdong Severance Hospital, College of Medicine, Yonsei University, 146 92 Dogok dong, Kangnam Ku, Seoul, Republic of Korea
    Diabetes Res Clin Pract 66:S139-44. 2004
    ..Conclusively, sibutramine improved fat distribution and insulin resistance, and increased serum adiponectin levels in Korean obese nondiabetic premenopausal women...
  44. ncbi Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study
    H Hauner
    German Diabetes Research Institute, Dusseldorf, Germany
    Exp Clin Endocrinol Diabetes 112:201-7. 2004
    ..Sibutramine is a selective serotonin and noradrenaline reuptake inhibitor that is known to reduce body weight. The efficacy of this drug in primary care medicine is currently unknown...
  45. ncbi Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    Diabetes Nutr Metab 17:222-9. 2004
    ....
  46. ncbi Squaraine-derived rotaxanes: sterically protected fluorescent near-IR dyes
    Easwaran Arunkumar
    Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, USA
    J Am Chem Soc 127:3288-9. 2005
    ..It should be possible to prepare squaraine-derived rotaxanes with improved properties for a wide range of photophysical, photochemical, and biomedical applications...
  47. ncbi Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies
    Roberto Vettor
    Department of Medical and Surgical Sciences, Endocrine Metabolic Laboratory, University of Padua, Via Ospedale 105, 35128 Padua, Italy
    Diabetes Care 28:942-9. 2005
    ..The aim of this study was to provide a comprehensive meta-analysis of randomized controlled clinical studies on the effects of sibutramine on weight loss and glycemic control in obese subjects with type 2 diabetes...
  48. ncbi Two-year outcome of a combination of weight loss therapies for type 2 diabetes
    J Bruce Redmon
    Division of Endocrinology and Diabetes, Department of Medicine, University of Minnesota, MMC 101, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Diabetes Care 28:1311-5. 2005
    ..To evaluate the effects over 2 years of a weight loss program combining several weight loss strategies on weight loss and diabetes control in overweight subjects with type 2 diabetes...
  49. ncbi A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain
    David C Henderson
    Schizophrenia Program, Weight Center, Endocrine Unit, and Biostatistics Center, Massachusetss General Hospital, Boston, USA
    Am J Psychiatry 162:954-62. 2005
    ..This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder...
  50. ncbi Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Bispebjerg Bakke 23, Copenhagen 2400 NV, Denmark
    Eur Heart J 28:2915-23. 2007
    ..The study had an initial single-blind, 6-week lead-in period with sibutramine plus weight management. We report the cardiovascular responses and weight loss during this period...
  51. ncbi Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism
    Hans Hauner
    German Diabetes Research Institute, D 40225 Dusseldorf, Germany
    Pharmacogenetics 13:453-9. 2003
    ..However, a significant variability exists among individuals concerning the response to sibutramine...
  52. ncbi Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis
    Karl Horvath
    EBM Review Center, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    Arch Intern Med 168:571-80. 2008
    ..2 mm Hg). In patients with essential hypertension, therapy with a weight loss diet or orlistat resulted in reductions in body weight and BP. Although sibutramine treatment reduced body weight, it did not lower BP...
  53. ncbi Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial
    T A Wadden
    University of Pennsylvania School of Medicine, Department of Psychiatry, Philadelphia 19104, USA
    Obes Res 8:431-7. 2000
    ..This study assessed whether adding orlistat to sibutramine would induce further weight loss in patients who previously had lost weight while taking sibutramine alone...
  54. ncbi Sibutramine-associated adverse effects: a practical guide for its safe use
    M Florentin
    Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
    Obes Rev 9:378-87. 2008
    ..Hypertension, if adequately treated and frequently monitored, is not an absolute contraindication for the prescription of sibutramine...
  55. ncbi Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
    K Fujioka
    Nutrition and Metabolic Research Center, Scripps Clinic, San Diego, CA 92130, USA
    Diabetes Obes Metab 2:175-87. 2000
    ..To determine the efficacy and tolerability of sibutramine hydrochloride in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent...
  56. ncbi The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity
    Adriane Maria Rodrigues
    SEMPR, Serviço de Endocrinologia e Metabologia do Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Brazil
    J Clin Endocrinol Metab 87:1621-6. 2002
    ....
  57. ncbi Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial
    T A Wadden
    Department of Psychiatry, University of Pennsylvania School of Medicine, 3600 Market St, Suite 738, Philadelphia, PA 19104, USA
    Arch Intern Med 161:218-27. 2001
    ..Weight loss medications are recommended as an adjunct to diet and exercise modification but seem to be prescribed as a monotherapy by many physicians. This practice is likely to be associated with suboptimal weight loss...
  58. ncbi Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes
    Y J Hung
    Division of Endocrinology and Metabolism, Tri Service General Hospital, National Defense Medical Center, Taipei, Taiwan
    Diabet Med 22:1024-30. 2005
    ..To evaluate the effect of sibutramine on weight loss, insulin sensitivity and serum adiponectin levels in obese patients with Type 2 diabetes...
  59. ncbi Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial
    L F Van Gaal
    Department of Diabetology, Metabolism and Clinical Nutrition, Antwerp University Hospital, Belgium
    Diabetes Obes Metab 12:26-34. 2010
    ..To assess treatment responses to sibutramine and weight management in diabetic patients during the lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial...
  60. ncbi Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats
    C N Boozer
    New York Obesity Research Center, St. Luke's-Roosevelt Hospital Center, New York, NY 10025, USA
    Metabolism 50:889-93. 2001
    ..Replacement doses of L during S administration increased weight loss and fractional fat loss by (1) decreasing food intake and (2) by increasing fat oxidation. Such drug combinations may be useful in the treatment of human obesity...
  61. ncbi Transient global amnesia after taking sibutramine: a case report
    Pin Kuei Fu
    Division of Neurology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan, Republic of China
    Neurologist 16:129-31. 2010
    ..Although amnesia and seizure is listed as a reported adverse event of sibutramine in the US product information, our literature search in the PubMed website database found no published reports of theses adverse events...
  62. pmc Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study
    Russell M Viner
    General and Adolescent Paediatrics Unit, UCL Institute of Child Health, University College London, London, UK
    Br J Clin Pharmacol 68:844-51. 2009
    ..The antiobesity drugs sibutramine and orlistat are not licensed for use in children and adolescents in the UK or USA. * Clinical trials suggest antiobesity drugs are effective and well-tolerated in obese adolescents...
  63. ncbi Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
    Asa Lindholm
    Department of Obstetrics and Gynecology, Sunderby Hospital, Lulea, Sweden
    Fertil Steril 89:1221-8. 2008
    ..To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS)...
  64. ncbi Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials
    J Jordan
    Franz Volhard Clinical Research Center and HELIOS Klinikum, Medical Faculty of the Charite, Humboldt University, Berlin, Germany
    Int J Obes (Lond) 29:509-16. 2005
    ..Sibutramine, a serotonin and norepinephrine transporter inhibitor, is widely used as an adjunctive obesity treatment. There have been concerns that norepinephrine reuptake inhibition with sibutramine could exacerbate arterial hypertension...
  65. ncbi Sibutramine produces dose-related weight loss
    G A Bray
    Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
    Obes Res 7:189-98. 1999
    ..This paper reports a 24-week dose-ranging study to determine the effect of sibutramine on body weight of patients with obesity...
  66. ncbi Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
    Stephan von Haehling
    Eur Heart J 28:2830-1. 2007
  67. ncbi Long-term persistence with orlistat and sibutramine in a population-based cohort
    R Padwal
    Division of General Internal Medicine, Walter C Mackenzie Health Sciences Center, University of Alberta Hospital, 8440 112th Street, Edmonton, Alberta, Canada
    Int J Obes (Lond) 31:1567-70. 2007
    ..The objective of this study was to determine the long-term persistence with orlistat and sibutramine therapy outside a clinical trial setting...
  68. pmc Chinese slimming capsules containing sibutramine sold over the Internet: a case series
    Dieter Muller
    Giftinformationszentrum Nord, Zentrum Pharmakologie und Toxikologie Göttingen, Germany
    Dtsch Arztebl Int 106:218-22. 2009
    ..We report 17 cases of poisoning with a single product, said to be of purely herbal origin, that was bought over the Internet. A complete declaration of the ingredients was not available...
  69. ncbi The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
    D L Hansen
    Research Department of Human Nutrition, The Royal Veterinary and Agricultural University, Rolighedsvej 30, Frederiksberg C, Denmark
    Int J Obes Relat Metab Disord 23:1016-24. 1999
    ..To assess the contribution of a thermogenic effect to weight loss induced by eight weeks treatment with sibutramine (15mg/d) vs placebo in obese subjects...
  70. ncbi Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine
    V Hainer
    Institute of Endocrinology, Obesity Management Centre, Prague, Czech Republic
    Int J Obes (Lond) 29:208-16. 2005
    ..The impact of changes in psychobehavioral and nutritional markers observed after 4 and 12 months of treatment on BMI changes was also investigated...
  71. ncbi Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review
    M Neovius
    Department of Medicine, Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden
    Int J Obes (Lond) 32:1752-63. 2008
    ..To review economic evaluations of weight loss drugs and compare reported incremental cost-effectiveness ratios (ICERs)...
  72. ncbi Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients
    N Finer
    Wellcome Trust Clinical Research Facility, Cambridge, UK
    Diabetes Obes Metab 8:206-13. 2006
    ..This regimen may deny treatment to a large group of patients who might otherwise benefit, particularly patients with type 2 diabetes who often find it more difficult to lose weight than non-diabetic obese individuals...
  73. ncbi Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance
    W P James
    Rowett Research Institute, Aberdeen, UK
    Lancet 356:2119-25. 2000
    ..We did a randomised, double-blind trial to assess the usefulness of sibutramine in maintaining substantial weight loss over 2 years...
  74. ncbi Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment
    Karsten Heusser
    Franz Volhard Clinical Research Center, Medical Faculty of the Charité and HELIOS Klinikum, Berlin, Germany
    J Clin Endocrinol Metab 92:1560-3. 2007
    ..The serotonin and norepinephrine transporter inhibitor sibutramine is a widely used antiobesity drug. In acute studies, the peripheral sympathomimetic effect of sibutramine was counteracted by a central sympatholytic action...
  75. ncbi Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study
    D N Kiortsis
    Laboratory of Physiology, Medical School, University of Ioannina, Panepistimiou Avenue, 45110 Ioannina, Greece
    Nutr Metab Cardiovasc Dis 18:207-10. 2008
    ..Moreover, no study has evaluated the effects of orlistat treatment on mood. The purpose of our study was to assess the effects of sibutramine and orlistat on mood in obese and overweight subjects...
  76. ncbi Sibutramine therapy in obese women--effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations
    Bogusława Baranowska
    Department of Neuroendocrinology, Marymoncka 99, 01 813 Warsaw, Poland
    Neuro Endocrinol Lett 26:675-9. 2005
    ..The aim of this study was to evaluate the effects of the sibutramine therapy on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations in obese patients...
  77. ncbi Randomized trial of lifestyle modification and pharmacotherapy for obesity
    Thomas A Wadden
    University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    N Engl J Med 353:2111-20. 2005
    ..This practice is likely to limit therapeutic benefits...
  78. ncbi Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study
    E M H Mathus-Vliegen
    Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Eur J Clin Nutr 59:S31-8; discussion S39. 2005
    ..However, long-term maintenance of weight loss is generally poor. We assessed the efficacy and safety of sibutramine in maintaining weight loss achieved in obese patients by means of a 3-month VLCD...
  79. pmc QT interval prolongation associated with sibutramine treatment
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, New Zealand
    Br J Clin Pharmacol 61:464-9. 2006
    ..To investigate a possible association of sibutramine with QT interval prolongation...
  80. ncbi A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain
    D C Henderson
    The Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 115:101-5. 2007
    ..This study sought to examine the effectiveness of sibutramine, a weight loss agent, on clozapine-associated weight gain...
  81. ncbi Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes
    Pernilla Danielsson
    Department of Pediatrics and the National Childhood Obesity Centre, B57, Karolinska University Hospital, Huddinge, S 141 86 Stockholm, Sweden
    J Clin Endocrinol Metab 92:4101-6. 2007
    ..The combination of comorbidities and severe obesity lower the quality of these children's lives drastically. The present goal was to determine whether treatment with sibutramine has a beneficial effect on such children...
  82. ncbi Orlistat and sibutramine beyond weight loss
    Edoardo Mannucci
    Section of Endocrinology, Department of Clinical Pathophysiology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy
    Nutr Metab Cardiovasc Dis 18:342-8. 2008
    ..To investigate, through a meta-analysis of clinical trials, the effect of two weight-reducing drugs, such as orlistat and sibutramine, on serum lipid profiles in overweight and obese subjects, independently of weight loss...
  83. ncbi Sympathetic-leptin relationship in obesity: effect of weight loss
    Didier Quilliot
    centre d investigation clinique, INSERM CHU, Nancy, France
    Metabolism 57:555-62. 2008
    ..Our results imply therefore that the relationship between leptin and the autonomic nervous system is disturbed in normotensive obese subjects...
  84. ncbi The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England
    Michael J Perrio
    Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, United Kingdom S031 1AA
    Obesity (Silver Spring) 15:2712-22. 2007
    ..Adverse events reported as case reports were also evaluated to determine whether these events were also identified by PEM...
  85. ncbi Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study
    D Florakis
    Second Department of Obstetrics and Gynecology, Division of Endocrinology and Human Reproduction, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Int J Obes (Lond) 32:692-9. 2008
    ..To examine the effect of hypocaloric diet plus sibutramine on body composition, hormonal and metabolic parameters in overweight and obese patients with polycystic ovary syndrome (PCOS)...
  86. ncbi Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis
    M Neovius
    Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Obes Rev 9:420-7. 2008
    ..3-1.4) indicating lower dropout for sibutramine. This information together with an understanding of the clinical properties of each drug should help to guide the prescribing physician in the selection of adequate drug therapy for obesity...
  87. ncbi The effect of sibutramine on energy expenditure and body composition in obese adolescents
    Edgar G A H Van Mil
    Department of Methodology and Statistics and Human Biology, Nutrition Environment and Toxicology Research Institute Maastrict, Maastrict University, and Department of Pediatrics, University Hospital Maastrict, The Netherlands
    J Clin Endocrinol Metab 92:1409-14. 2007
    ..Childhood obesity is now considered to be an epidemic. Drug therapy in this age group remains a topic of research...
  88. pmc Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice
    Haoran Su
    The National Center for Drug Screening, Shanghai, China
    PLoS ONE 3:e2892. 2008
    ..The present study was aimed at determining the in vivo pharmacologic properties of Boc5 in both normal and diabetic mice following chronic administration, with emphasis on glycemic control and weight loss...
  89. ncbi Sibutramine-associated QT interval prolongation and cardiac arrest
    David Ernest
    Box Hill Hospital, Victoria, Australia
    Ann Pharmacother 42:1514-7. 2008
    ..To report on a probable association between sibutramine and QT interval prolongation leading to ventricular fibrillation and cardiac arrest...
  90. ncbi Incorrect use of orlistat and sibutramine in clinical practice
    Anna Dahlin
    Medical Products Agency, P O Box 26, 751 03 Uppsala, Sweden
    Eur J Clin Pharmacol 63:205-9. 2007
    ..To investigate how the antiobesity drugs orlistat and sibutramin are prescribed in relation to the approved indications and the Swedish subsidiary rules...
  91. ncbi Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study
    A Wirth
    Teutoburger Wald Klinik, Bad Rothenfelde, Germany
    Diabetes Obes Metab 8:674-81. 2006
    ..Following body weight reduction, the left ventricular mass (LVM) is reduced. It is not known to which extent this occurs after treatment with sibutramine...
  92. pmc A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days
    J A Gietema
    Department of Internal Medicine, University Hospital, Groningen, The Netherlands
    Br J Cancer 67:396-401. 1993
    ..The recommended dose of lobaplatin i.v. bolus daily for 5 days for phase II studies depends on renal function, namely 30 mg m-2 at CRCL 60-80 ml min-1; 55 mg m-2 at CRCL 81-100 ml min-1; 70 mg m-2 at CRCL > 100 ml min-1...
  93. ncbi NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine
    Ngozi Erondu
    Merck Research Laboratories, 126 E Lincoln Avenue, PO Box 2000, RY34A Rahway, NJ 07065 0900, USA
    Obesity (Silver Spring) 15:2027-42. 2007
    ..This study evaluated whether blockade of the NPY Y5 receptor (NPY5R) with the selective antagonist MK-0557 potentiates sibutramine and orlistat weight loss effects...
  94. ncbi The efficacy and safety of sibutramine for weight loss: a systematic review
    David E Arterburn
    Department of Veterans Affairs, Puget Sound Health Care System, Seattle, WA, USA
    Arch Intern Med 164:994-1003. 2004
    ..We conducted a systematic review to assess the efficacy and safety of sibutramine hydrochloride for weight loss...
  95. ncbi Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction
    Faiez Zannad
    Centre d Investigation Clinique INSERM, CHU de Nancy, Hopital Jeanne d Arc, Toul, France
    Am Heart J 144:508-15. 2002
    ..In obese subjects, weight reduction regresses LV mass (LVM), regardless of blood pressure. Sibutramine can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss...
  96. ncbi Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women
    Warren R Peters
    Loma Linda University, Center for Health Promotion, Loma Linda, California 92350, USA
    Obes Res 11:415-9. 2003
    ..To understand the impact of the phenylethanolamine N-methyltransferase (PNMT) G-148A gene and nutritional variables on weight loss in obese women...
  97. ncbi Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, 2 27100 Pavia, Italy
    Diabetes Obes Metab 7:47-55. 2005
    ....
  98. ncbi Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study
    Amelio Godoy-Matos
    Nutrology and Metabolism Department, Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione, Rua Visconde Silva, 52 704 Botafogo, 22271 090, Rio de Janeiro, Brazil
    J Clin Endocrinol Metab 90:1460-5. 2005
    ..There were no changes in echocardiographic parameters. In conclusion, sibutramine plus diet and exercise induced significantly more weight loss in obese adolescents...
  99. ncbi Combined dietary and pharmacological weight management in obese hypopituitary patients
    Henriette Mersebach
    Department of Endocrinology, Copenhagen University Hospital 9, Blegdamsvej DK 2100 Copenhagen, Denmark
    Obes Res 12:1835-43. 2004
    ..In this study, we investigated the combined effect of sibutramine, diet, and exercise in obese hypopituitary patients (HPs)...
  100. ncbi Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome
    B Barkeling
    Obesity Unit, Institute of Internal Medicine, Huddinge University Hospital, Stockholm, Sweden
    Int J Obes Relat Metab Disord 27:693-700. 2003
    ..To evaluate the short-term effects of sibutramine on appetite and eating behaviour and whether these effects are related to the long-term therapeutic outcome...
  101. ncbi Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients
    Ayca Kaya
    Haydarpasa Numune Training and Research Hospital, 5th Department of Internal Medicine, Istanbul, Turkey
    Biomed Pharmacother 58:582-7. 2004
    ..To describe encountered adverse effects...

Research Grants40

  1. Development of Cyclopropyl Metal Carbene Based Methods for Organic Synthesis
    Weiping Tang; Fiscal Year: 2013
    ..methods based on cyclopropyl metal carbenes will be developed for the synthesis of highly functionalized cyclobutanes, pyrans, and other complex ring systems under mild catalytic conditions...
  2. Behavioral factors in the surgical treatment of obesity
    Thomas Wadden; Fiscal Year: 2009
    ..The study, by examining ghrelin and other appetite-related hormones, also will enhance knowledge of the regulation of body weight following GBP. ..
  3. LIFESTYLE ACTIVITY FOR WEIGHT MANAGEMENT
    Thomas Wadden; Fiscal Year: 2003
    ..The predicted superiority of lifestyle activity is based on extensive pilot data and, if confirmed, should significantly improve the management of obesity and its associated health complications. ..
  4. BEHAVIOR MODIFICATION AND PHARMACOTHERAPY FOR OBESITY
    Thomas Wadden; Fiscal Year: 2002
    ..If confirmed, the above findings will have important implications for treating obesity in primary care. ..
  5. Louisiana Clinical and Translational Science Center Planning Phase
    Donna Ryan; Fiscal Year: 2006
    ..In addition to activities serving Louisiana, the LA CaTS Center will serve as an incubator to foster the development of innovative tools and information technologies that can benefit the field. [unreadable] [unreadable] [unreadable]..
  6. Synthesis of Macrolides, Steroids, Cyclopentanoids, etc.
    BARRY TROST; Fiscal Year: 2009
    ..These new synthetic methods apply to many structural types beyond those illustrated and constitutes a significant to gain access to complex molecular targets more easily. ..
  7. TUMOR REMISSION--TAXOL AND CLOSE ANALOGS VIA SYNTHESIS
    LEO PAQUETTE; Fiscal Year: 2003
    ..These include, but are not limited to, the 1-deoxy, D-homo-, 2-desmethyl, and 12-methylene derivatives, in addition to the D-ring invertomer and the C-nor isomer. ..
  8. Aripiprazole for Clozapine Associated Medical Morbidity
    David Henderson; Fiscal Year: 2007
    ..Clinical adjunctive therapy may establish aripiprazole as a new therapeutic approach in schizophrenia and clozapine-associated medical disorders. ..
  9. Effectiveness of Psychological Treatment for BED
    Denise Wilfley; Fiscal Year: 2006
    ..This study promises to not only clarify the most efficacious overall treatment for individuals with BED, but also to identify sub-groups for whom specific treatments are indicated. ..
  10. SITES AND MECHANISMS OF INHALED ANESTHETIC ACTIONS
    EDMOND EGER; Fiscal Year: 2008
    ..abstract_text> ..
  11. DIETARY OBESITY
    George Bray; Fiscal Year: 2007
    ..We now propose these well founded, important and exciting studies which will provide critical new insights into anatomical, physiological and molecular mechanisms by which high levels of dietary fat induce obesity. ..
  12. 2/2-Preventing Eating Disorders and Reducing Comorbidity
    DENISE ELLA WILFLEY; Fiscal Year: 2010
    ..If so, this finding, combined with our previous research would have a major public health impact on reducing eating disorder rates. ..
  13. Childhood Obesity Treatment: A Maintenance Approach
    DENISE ELLA WILFLEY; Fiscal Year: 2010
    ....
  14. Bipolar II Depression: Lithium, SSRI or the Combination
    Susan L McElroy; Fiscal Year: 2010
    ..We also hypothesize that the frequency of side effects will be significantly less in patients on SSRI monotherapy. Thus, secondary aims include assessment of patient satisfaction, which may affect compliance in the clinical setting. ..
  15. DIENCEPHALIC MECHANISMS OF DRUG ABUSE
    STANLEY GLICK; Fiscal Year: 2008
    ..The work proposed here may ultimately result in new kinds of treatments for drug abuse. ..
  16. PHARMACOLOGY & NEUROSCIENCE TRAINING IN DRUG ABUSE
    STANLEY GLICK; Fiscal Year: 2008
    ..All aspects of the program are administered by the director and an executive committee of administrative and training faculty. ..
  17. Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
    MICHAEL L CAMILLERI; Fiscal Year: 2010
    ..These actions may be relevant to develop new treatments for IBS. The studies will also provide further understanding of the potential of medications like medical marijuana on stomach function that may be relevant to appetite control. ..
  18. Molecular Target Focused Discovery of Anticancer Drugs
    GEORGE PETTIT; Fiscal Year: 2007
    ..In summary, the proposed research will be sharply aimed at the discovery and very rapid development of new anticancer drugs for the NCI programs direct at improving human cancer treatments. ..
  19. Inhibitors of Hedgehog Signaling For Brain Cancer Chemotherapy
    JEFFREY D contact WINKLER; Fiscal Year: 2010
    ..The studies outlined herein therefore hold the promise of developing important new tools in cancer biology and new drug candidates for the treatment of brain cancers. ..
  20. WEIGHT CONNECTION: WEIGHT LOSS MAINTANANCE USING THE WEB
    Lee Kaplan; Fiscal Year: 2001
    ..abstract_text> ..
  21. Heavy Metal and Drug Self-Administration: Mechanisms
    PAUL JEFFERSON WELLMAN; Fiscal Year: 2010
    ..e., lead contamination and cocaine use. Based on the available literature, there is reason to believe that environmental pollutants may increase vulnerability to drug addiction. ..
  22. ANESTHETIC SITES IN TRANSMEMBRANE PEPTIDES BY NMR
    Pei Tang; Fiscal Year: 2008
    ..The results of this investigation will lead to a new paradigm for the analysis and interpretation of general anesthetic action on neuronal proteins. ..
  23. ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME
    Michael Camilleri; Fiscal Year: 2008
    ..Significance: This project will characterize pharmacogenetic mechanisms determining the response to clonidine through studies of candidate genes that control alpha2-adrenoreceptor function and norepinephrine transport in IBS. ..
  24. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2007
    ..abstract_text> ..
  25. CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESES
    Michael Doyle; Fiscal Year: 2002
    ..4 percent ee). Finally, enantioselective cyclopropanation with diazo-methane, which has been elusive, will be examined in critical detail using chiral copper(I) and dirhodium(II) catalysts. ..
  26. METABOLIC FACTORS ASSOCIATED WITH LONG-TERM WEIGHT LOSS
    Holly Wyatt; Fiscal Year: 2003
    ..These are important skills and experiences for the candidate's career plan. ..
  27. SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS
    ROBERT BOECKMAN; Fiscal Year: 2002
    ..The hypothesis that an internal chelate of suitably disposed oxygen functions permits the modification of the ring conformation from half-chair to half-boat will be tested. ..
  28. METABOLIC CONSEQUENCES OF ANTIRETROVIRAL THERAPY
    DAVID WEIGLE; Fiscal Year: 2003
    ..Future trials of these medications, along with a great deal more basic research, are clearly justified by the increasing and sustained use of HAART to deal with the worldwide epidemic of HIV infection. ..
  29. Synthesis of Bioactive Substances
    Jeffrey Winkler; Fiscal Year: 2003
    ..abstract_text> ..
  30. Catalytic Processes for Selective Organic Synthesis
    GARY MOLANDER; Fiscal Year: 2005
    ..4) Carbometalation/cyclization reactions will be explored utilizing organochromium species. 5) Ligands and catalytic systems designed for asymmetric synthesis will be explored. ..
  31. STUDIES OF REGIONAL FAT DISTRIBUTION AND ENERGY BALANCE
    DAVID WEIGLE; Fiscal Year: 2005
    ..The applicant has successfully trained several young physician investigators in patient-oriented and basic research, and a plan to continue doing so is presented. ..
  32. VASCULAR EFFECTS OF HOMOCYSTEINE IN HUMANS
    WILLIAM HAYNES; Fiscal Year: 2005
    ..The results may also suggest novel potential therapeutic approaches to be tested in future outcome trials. ..
  33. Vinylogous Amide Photochemistry in Organic Synthesis
    Jeffrey Winkler; Fiscal Year: 2005
    ..abstract_text> ..
  34. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 2005
    ..Overall, this research program is expected to be of significant value in chemistry, biology, and medicine. ..
  35. Psychostimulants and Alpha-1 Adrenoceptor Subtypes
    Paul Wellman; Fiscal Year: 2006
    ..These studies will advance our understanding of the behavioral functions of brain a l-AR subtypes and may lead to the identification of new drugs that inhibit eating without activating brain reinforcement systems. ..
  36. IV COCAINE ABUSE TREATMENT: A LABORATORY MODEL
    RICHARD FOLTIN; Fiscal Year: 2007
    ..abstract_text> ..
  37. Agilent 5973 GC/MS System
    GARY MOLANDER; Fiscal Year: 2002
    ..Our current lack of such instrumentation negatively affects the ability to carry out many of these studies. This critical capability, in the form of an instrument for everyday analysis, is urgently needed. ..
  38. LABORATORY ANALYSIS OF COCAINE ABSTINENCE
    RICHARD FOLTIN; Fiscal Year: 2007
    ..abstract_text> ..
  39. NEUROBEHAVIORAL MECHANISMS OF DRUG ADDICTION
    STANLEY GLICK; Fiscal Year: 2001
    ..This research may result in novel treatments for addictive disorders in humans. ..
  40. Molecular Target Focused Discovery of Anticancer Drugs
    George R Pettit; Fiscal Year: 2010
    ....